Microba Life Sciences (ASX:MAP) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Microba Life Sciences 5-Year Yield-on-Cost %?

Microba Life Sciences ASX:MAP 5-Year Yield-on-Cost % is 0.00 as of Jul. 15, 2026. The stock has 6 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, Microba Life Sciences ranks worse than 1562498.44% on this metric.

Microba Life Sciences's yield on cost for the quarter that ended in Dec. 2025 was 0.00.


The historical rank and industry rank for Microba Life Sciences's 5-Year Yield-on-Cost % or its related term are showing as below:



ASX:MAP's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.455
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Microba Life Sciences  (ASX:MAP) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Microba Life Sciences 5-Year Yield-on-Cost % Related Terms

ASX:MAP vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison

For the Diagnostics & Research subindustry, Microba Life Sciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microba Life Sciences 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Microba Life Sciences's 5-Year Yield-on-Cost % falls into.


Microba Life Sciences 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Microba Life Sciences is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Microba Life Sciences (ASX:MAP) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Microba Life Sciences and its competitors. According to the industry distribution chart, Microba Life Sciences ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry.
Is Microba Life Sciences' 5-Year Yield-on-Cost % too high?
Microba Life Sciences' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Microba Life Sciences ranks #999999 out of 64 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Microba Life Sciences' 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #999999 out of 64 companies for 5-Year Yield-on-Cost %. This places Microba Life Sciences in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.46, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.26, compared to a current price of A$0.04 — trading 84.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microba Life Sciences Business Description

Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.